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Cancer Therapy: Preclinical
TH-302 in Combination with Radiotherapy
Enhances the Therapeutic Outcome and Is
Associated with Pretreatment [18F]HX4 Hypoxia
PET Imaging
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Ruud G.P.M. van Stiphout1, Ala Yaromina1, Jessica D. Sun2, Charles P. Hart2,
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Abstract
Purpose:Conventional anticancer treatments are often impaired
by thepresenceofhypoxia. TH-302selectively targetshypoxic tumor
regions, where it is converted into a cytotoxic agent. This study
assessed the efficacy of the combination treatment of TH-302 and
radiotherapy in two preclinical tumor models. The effect of oxygen
modification on the combination treatment was evaluated and the
effect of TH-302 on the hypoxic fraction (HF) wasmonitored using
[18F]HX4-PET imaging and pimonidazole IHC stainings.
Experimental Design: Rhabdomyosarcoma R1 and H460
NSCLC tumor-bearing animals were treated with TH-302 and
radiotherapy (8 Gy, single dose). The tumor oxygenation status
was altered by exposing animals to carbogen (95% oxygen) and
nicotinamide, 21% or 7% oxygen breathing during the course of
the treatment. Tumor growth and treatment toxicity were moni-
tored until the tumor reached four times its start volume (T4SV).
Results: Both tumor models showed a growth delay after
TH-302 treatment, which further increased when combined
with radiotherapy (enhancement ratio rhabdomyosarcoma
1.23; H460 1.49). TH-302 decreases the HF in both models,
consistent with its hypoxia-targeting mechanism of action.
Treatment efficacy was dependent on tumor oxygenation;
increasing the tumor oxygen status abolished the effect of
TH-302, whereas enhancing the HF enlarged TH-3020s thera-
peutic effect. An association was observed in rhabdomyosar-
coma tumors between the pretreatment HF as measured by
[18F]HX4-PET imaging and the T4SV.
Conclusions: The combination of TH-302 and radiotherapy is
promising and warrants clinical testing, preferably guided by the
companion biomarker [18F]HX4 hypoxia PET imaging for patient
selection. Clin Cancer Res; 21(13); 2984–92. 2015 AACR.
Introduction
Hypoxia is a common feature of solid tumors and is known to
negatively influence treatment outcome (1, 2). Because of the
disorganized vessel formation and consequently low oxygen
concentrations, conventional chemotherapies and radiotherapies
are less effective. To overcome hypoxia-induced treatment resis-
tance, drugs have been developed that specifically target hypoxic
tumor regions. These so-called "hypoxia-activated prodrugs"
(HAP) are nontoxic under normal oxygen concentrations but
are activated in environments with low oxygen concentrations.
TH-302 is a second-generation HAP of which the activation
mechanism is based on the reduction of its 2-nitroimidazole
moiety. Only in the presence of certain reductases under low
oxygen concentrations is the toxic effector bromo-isophosphor-
amidemustard (Br-IPM) selectively released and able to crosslink
DNA leading to cell death.
Preclinical studies have assessed the therapeutic effect of TH-302
alone or in combination with conventional chemotherapies in
multiple xenograft models. TH-302 monotherapy led to reduced
tumor growth in many of the xenograft models profiled, and was
dependenton thehypoxic fraction (HF; ref. 3).CombiningTH-302
with several clinically used chemotherapeutics offers advantage
over single-agent treatment, although the treatment schedule and
order of administration are of importance (4). A phase I study
demonstrated the safety of TH-302 monotherapy in patients with
solid malignancies (5). Other clinical phase I and II trials success-
fully combined the standard treatment doxorubicin with intrave-
nous administration of TH-302 in patients with advanced soft
tissue sarcoma(6, 7) and standard treatment gemcitabinewithTH-
302 in patients with advanced pancreatic cancer (8).
However, there are no published studies to assess the combi-
nation therapy of TH-302 and radiotherapy. Radiotherapy is one
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of the conventional treatment options applied to multiple cancer
types and tumor hypoxia is a known radioresistance factor. The
combination of TH-302 and radiotherapy is hypothesized to be
complementary; where TH-302 specifically targets hypoxic cells,
radiotherapy has the highest therapeutic gain in the well-oxygen-
ated cells.
PET imaging is a noninvasive method characterizing the tumor
oxygenation status in a three-dimensional manner. Several PET
tracers have been developed that specifically visualize hypoxic
regions. One of those tracers, based on the same 2-nitroimidazole
hypoxia sensing mechanism as TH-302, is [18F]HX4. Preclinical
and clinical trials have shown that [18F]HX4 is a reliable tool for
the noninvasive detection of hypoxic tumor regions (9–11).
Because TH-302, like tirapazamine, is expected to have only a
therapeutic effect when hypoxic regions are present in the tumor
(12), [18F]HX4 PET imaging may function as a useful predictive
biomarker.
In the current study, we investigated the treatment effect of TH-
302 in combination with radiotherapy in two preclinical tumor
models. We hypothesize that this combination therapy will
enhance the therapeutic effect. Furthermore, we investigate the
causal relationship between TH-302 efficacy and the modified
tumor oxygenation status which was assessed before and after
treatment using [18F]HX4 hypoxia PET imaging and only after
treatment with pimonidazole staining. We hypothesize that the
pretreatment hypoxia [18F]HX4 PET imaging will correlate with
the treatment outcome.
Materials and Methods
Animal, tumor models, and treatment schedules
All animal experimental procedures were approved by the
Animal Ethical Committee of Maastricht University (Maastricht,
the Netherlands) and were in accordance with the Helsinki
Declaration of 1975 as revised in 2000. All animals were mon-
itored at least three times a week and their tumor volume was
calculatedusing the formula: ABCp/6, inwhichA, B, andC
are the three orthogonal diameters of the tumor as measured
using a Vernier caliper, each corrected for the thickness of the skin.
Animals were randomized into the different treatment groups
(Supplementary Fig. S1A) and were monitored until four times
start volume (T4SV) was reached. For this calculation, the start
volumeof thefirst day of TH-302 treatmentwas used andfitting of
the data was based on the regrowth phase. TH-302 was supplied
by Threshold Pharmaceuticals and dissolved in 0.9% NaCl to a
concentration of 5 mg/mL.
Experimental models
Syngeneic rhabdomyosarcoma R1 tumors (1 mm3) were
implanted subcutaneously in the lateral flank of adult WAG/Rij
rats. Experiments were started upon a mean tumor volume of
4.2 cm3 (range, 2.0–8.1) to ensure a stable HF. Treatment was
administered on 4 consecutive days (Supplementary Fig. S1A)
and consisted of an intraperitoneal injection (i.p.; QD4) with
either NaCl or TH-302 (25, 50, or 75 mg/kg). Before the start of
treatment, a PET scan was made using [18F]HX4. Radiotherapy
(Varian Truebeam linear accelerator; 15 MeV electrons) was
applied in a single dose of 0, 4, 8, or 12 Gy on day 3 of the
treatment, 3 hours after NaCl or TH-302 injection, 1 hour after
oxygenmodification.During bothPET imaging and radiotherapy,
rats were anesthetized using a mixture of ketamine/xylazine (i.p;
66.7 and 6.7 mg/kg, respectively). During the 5 days of treatment
(1 day PET imaging, 4 days of injections with TH-302 or vehicle),
animals were exposed to modified oxygen concentrations for 4
hoursperday inorder toalter theHFof the tumor.The combination
oxygen modification of nicotinamide (i.p. 500 mg/kg) and carbo-
gen (95% oxygen, 5% CO2; 5 L/minute) consisted of a nicotin-
amide injection and 30 minutes later the exposure to carbogen
breathing for 3.5 hours. In the middle of the nicotinamide/carbo-
gen treatment, NaCl/TH-302 was administered. Reduced oxygen
breathing (7%, residual N2; 2.5 L/minute) was given for 4 hours
with theNaCl/TH-302 injection after thefirst 2 hours. The injection
of the [18F]HX4 PET tracer [mean 18.8 MBq, range 7.1–25.1 MBq;
lateral tail vein using an intravenous line (Venoflux 0.4 mm G27)
flushed with 10% heparine)] was given 2 hours before the end of
the oxygenmodification. PET imaging was performed 3 hours after
tracer injection, as previously assessed (13). [18F]HX4 PET scans
could not be performed on all treated animals due to production
and supply difficulties. For the histologic control animals, PET
imaging was also performed on day 4 of the treatment.
H460 lung carcinomacellswere resuspended (1106 cells/mL;
ATCC HTB-177) in Basement Membrane Matrix (Matrigel BD
Biosciences) and injected in the lateral flank of NU-Foxn1-nu
(NU/NU) mice. Experiments were started upon animals reaching
a mean tumor volume of 225 mm3 (range 89–273 mm3). Mice
were treated with either NaCl or TH-302 (50 mg/kg) for 5
consecutive days (QD5). Treatment was combined with radio-
therapy in a single dose of 0or 8Gyonday4 forwhich the animals
were anesthetized using a mixture of ketamine/xylazine (i.p; 66.7
and 6.7 mg/kg, respectively). During the 5 days of treatment,
animals were exposed to different oxygen concentrations; either a
combination of nicotinamide (500 mg/kg i.p.) and carbogen
breathing (95% oxygen, 5% CO2), 21% oxygen breathing (pres-
sured air) or 7% oxygen breathing (residual N2). Total treatment
time for all oxygen breathing schedules was 2.5 hours with
the NaCl/TH-302 injection given 1 hour after the start of the
treatment. Nicotinamide was administered 30 minutes before
carbogen breathing was started, which was then applied for
another 2 hours. Radiotherapy was given within 1 hour after the
oxygen treatment. Histologic controls were administered with
Translational Relevance
Radiotherapy is applied to 50% of all cancer patients and is
therefore an important cancer treatment modality. Hypoxia is
a feature of solid tumors that gives the opportunity of a tumor-
targeted approach. TH-302 is shown to be a promising hyp-
oxia-activated prodrug. Several clinical trials have already
demonstrated the applicability of TH-302 as a monotherapy
and in combination with chemotherapy. In this study, the
efficacy of the combination treatment of TH-302 and radio-
therapy was assessed in two preclinical tumor models: the rat
rhabdomyosarcoma model and the human non–small cell
lung cancer H460 xenograft model. Furthermore, we moni-
tored tumor hypoxia with an imaging biomarker used in
clinical trials. Upon TH-302 treatment, the hypoxic cells,
which are less sensitive to conventional anticancer therapies,
were significantly decreased. We believe that the current study
gives important directions for future clinical studies.
TH-302 and Radiotherapy Monitored by [18F]HX4 Imaging
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pimonidazole (60 mg/kg, i.p.; Hypoxyprobe kit, HP3-1000;
Bio-connect) and Hoechst 33342 (15 mg/kg, i.v.; Sigma-Aldrich)
1 hour and 1 minute before sacrificing, respectively, followed by
excisionof the tumors thatwere snap frozen in liquidnitrogenand
stored at 80 degrees Celsius until being processed.
PET image acquisition and analysis
Tracer synthesis of [18F]HX4 was performed as described pre-
viously (14). [18F]HX4 PET images were acquired and analyzed
using a clinical PET/CT scanner (Siemens Biograph 40, Siemens
Healthcare) as previously described (13). A volume of interest in
the heart (sphere with a radius of 3 mm) was defined as back-
ground region. The threshold to define the HFwas set at 4.5 times
the background uptake, because thismethod results in aHF that is
in agreement with the pimonidazole staining-based results of a
previous study on the rat rhabdomyosarcoma model (15).
IHC staining and analysis
Frozen H460 xenograft tumors were sectioned (5 mm) and
stained for hypoxia (pimonidazole), blood vessels (CD31) and
perfusion (Hoechst 33342). Sections were fixed using cold
acetone, rehydrated in TBS with 0.2% Tween-20 (TBST) and
preincubated with normal goat serum before exposing them
to the primary antibody rabbit anti-pimonidazole (1:150;
HP3-1000, Bio-connect) and rat anti-mouse CD31 (1:500; BD
biosciences). After washing with TBST, incubation with the
secondary antibody goat anti-rabbit Alexa594 (1:500) and goat
anti-rat Alexa488 (1:750, both Invitrogen) was performed.
Sections were mounted using fluorescent mounting medium
(DakoCytomation) and scanned for pimonidazole, blood ves-
sels, and perfusion. After scanning, sections were stained for
hematoxylin and eosin (H&E).
Images were acquired using an Olympus BX51WI microscope
equipped with a Hamamatsu EM-CCD C9100 digital camera, a
motorized stage (Ludl Mac 2000) and a 10 objective. Micro-
manager 1.4 software was used for automated image acquisition
(16). ImageJ version 1.49e (http://rsb.info.nih.gov/ij/) was used
to stitch the images and perform quantitative analyses. All image
recordings and analyses were performed by an investigator
blinded to the subject coding. Viable tumor tissue was first
delineated manually by excluding epidermis, stroma, and necrot-
ic tumor regions based on H&E staining. The thresholds were set
manually by two independent observers to discriminate signal
from background. Finally the relative HF, microvessel density,
and perfusion were calculated by determining the positive frac-
tion within the viable tumor area.
Statistical analysis
GraphPad Prism software (version 5.01 forWindows)was used
to perform statistical analyses. To determine the statistical signif-
icance of differences between two independent groups of vari-
ables, we used an unpaired t test, whereas for matched groups, a
paired t test was applied. A two-way ANOVA was performed in R
v3.0.1 to determine synergistic effects. P values <0.05 were con-
sidered to be significant.
Results
Combination of TH-302 and radiotherapy
The effect of TH-302 in combination with radiotherapy
was assessed in two tumor models, a rhabdomyosarcoma rat
syngeneic model and a H460 human non–small cell lung
cancer (NSCLC) xenograft mouse model. The treatment dose
of TH-302 for rhabdomyosarcoma was assessed in a "tolera-
bility" study, showing 25 mg/kg (QD4) to be the most
optimal dose without adverse effects (Supplementary Fig.
S2). This dose was therefore selected for further experiments.
The TH-302 treatment dose of 50 mg/kg (QD5) for H460 was
based on literature (3).
Inboth tumormodels, TH-302 treatment showed an inhibition
of the tumor growth, which was further reduced when TH-302
administration was combined with a single dose of radiotherapy
(8 Gy; Fig. 1A). The time to reach four times start volume
(T4SV, Fig. 1B) was significantly delayed upon TH-302 mono-
therapy from 12.4  1.7 (mean  SD) to 20.4  3.5 days for
rhabdomyosarcoma (P < 0.001) and 7.1 2.4 to 13.6 4.8 days
forH460 (P¼0.003). Comparedwith radiotherapy alone, T4SV
for the combination treatment was delayed from 24.9  3.0 to
30.8  5.9 for rhabdomyosarcoma (P ¼ 0.026) and from 16.9 
7.1 to 25.2  4.9 for H460 (P ¼ 0.014), resulting in an enhance-
ment ratio (ER) of 1.23 and 1.49, respectively (Fig. 1B and
Supplementary Tables S1 and S2). In addition, the effect of
TH-302 was also assessed in the rhabdomyosarcoma model in
combination with 4 and 12 Gy of radiotherapy, leading to an ER
of 1.28 and 1.59, respectively (Supplementary Fig. S3A and S3B
and Supplementary Table S1). TH-302 has a radiosensitizing
effect in both tumor models and all radiotherapy doses. More-
over, the effect of the combination therapy TH-302 and 12 Gy
radiotherapy in the rhabdomyosarcoma model was even
synergistic.
Hypoxic fraction
The effect of TH-302 on the HF in the rhabdomyosarcoma
model was assessed using [18F]HX4 hypoxia PET imaging and
revealed a significant decrease from a baseline of 23.1% 6.7%
to 2.5%  4.2% after TH-302 treatment (P < 0.001). NaCl
treatment, as expected, did not affect the HF (Fig. 1C). In the
H460 model, the HF was assessed immediately after the treat-
ment using histologic controls injected with pimonidazole. The
HF in subjects treated with TH-302 significantly decreased
compared with the control animals (NaCl: 7.8%  3.0%;
TH-302: 1.3%  0.5%; Fig. 1D).
Effect of oxygen modification on the efficacy of TH-302 and
radiotherapy
To investigate whether a causal relationship exists between TH-
302 efficacy and tumor oxygenation, the amount of oxygen
present in the tumor was modified on the days of TH-302
treatment by 7% or 95% oxygen breathing to increase or decrease
theHF, respectively. Oxygenmodificationwas performed 1 day in
advance for the rhabdomyosarcoma model in order to assess
the effect of this modification on the baseline HF using
[18F]HX4-PET imaging. Ambient air breathing animals had a
HF of 22.2% 13.8%. A significant reduction in the HF to 2.1%
 4.7% was seen after 95% oxygen breathing (P < 0.001),
whereas 7% oxygen breathing significantly increased the HF to
29.5%  14.7% (P ¼ 0.029; Fig. 2A). Exposing rhabdomyo-
sarcoma-bearing rats to increasing oxygen conditions abolished
the effect of TH-302 and reduced the T4SV from 20.4  3.5 to
15.3  2.5 days (P ¼ 0.007, Fig. 2B; Supplementary Fig. S3C
and Supplementary Table S1), whereas control animals had an
increased T4SV. Upon combination with radiotherapy, the
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T4SV of TH-302–treated tumors decreased from 30.8  5.9
(TH-302 þ radiotherapy) to 25.7  2.9 days (TH-302 þ
radiotherapy þ 95% O2). This is comparable with the T4SV
of 23.2  1.7 days for animals treated with NaCl þ radiother-
apy under 95% O2 conditions resulting in an ER of 1.11
(Supplementary Table S1). Exposing animals to 7% oxygen
breathing resulted in a T4SV of 22.6  4.2 days for TH-302,
which is significantly delayed compared with the animals
treated with NaCl (T4SV: 16.1  1.9, P ¼ 0.001), although
7% oxygen treatment itself also had an effect on tumor growth
in control animals. In the combination therapy of 7% oxygen
breathing with radiotherapy, animals treated with TH-302 had
a further reduction in the T4SV to 35.4  6.1 days with an ER
of 1.29 compared with the animals treated with NaCl (Sup-
plementary Fig. S3C and Supplementary Table S1).
Oxygen modification treatments were also applied to the
H460 model where reducing the HF resulted in a decreased
T4SV from 25.2  4.9 (TH-302 þ radiotherapy) to 20.2  7.0
(TH-302 þ radiotherapy þ 95% O2) for the combination
treatment. This decrease was not significant, however. The ER
of TH-302 under high oxygen concentration remained stable at
1.50 versus 1.49 at 21% O2 breathing. The tumor growth rate
itself was unaffected by 95% oxygen breathing (Fig. 2C and
Supplementary Fig. S3D and Supplementary Table S2).
Increasing the HF significantly enlarged the therapeutic poten-
tial of TH-302 compared with normal air breathing animals
(P¼ 0.011), resulting in a T4SV of 22.7 7.9 (T4SV TH-302
21% O2: 13.6  4.8). Although 7% oxygen breathing reduced
the tumor growth slightly, radiotherapy increased the tumor
growth of control animals under this condition. The effect of
Figure 1.
The combination of TH-302 and
radiotherapy (8 Gy) reduces tumor
growth in a rhabdomyosarcoma (n ¼
8) and H460 (n  8) tumor model. A,
growth curves; B, time to reach four
times start volume (T4SV). Animals
were treated with either control
(NaCl) or TH-302 administered to
the rhabdomyosarcoma model for
4 consecutive days with a dose of
25 mg/kg and for the H460 model for
5 consecutive days using a dose of
50 mg/kg. Radiotherapy was
performed on either the third or fourth
day of TH-302 treatment. The HF of
the control animals and the animals
treated with TH-302 was analyzed in
C for rhabdomyosarcoma (n ¼ 6)
both before and immediately after
treatment using [18F]HX4 hypoxia
PET imaging (top, representative
[18F]HX4 PET images with the
delineation of the total tumor volume
in black and the HF in red (bottom,
quantification of HF per group) and in
D for H460 (n ¼ 6) immediately
after treatment using pimonidazole
IHC staining [top, representative
stainings, with hypoxia
(pimonidazole) in green, perfusion
(Hoechst) in blue, and vessels (CD31)
in red]. The white scale bar indicates
500 mm. Bottom: quantification. Data,
mean SEM.  , P < 0.05;  , P <0.005;
 , P < 0.001;  , P < 0.0001.
TH-302 and Radiotherapy Monitored by [18F]HX4 Imaging
www.aacrjournals.org Clin Cancer Res; 21(13) July 1, 2015 2987
on July 22, 2021. © 2015 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst March 24, 2015; DOI: 10.1158/1078-0432.CCR-15-0018 
the TH-302 and radiotherapy combination increased to an ER
of 2.45 for TH-302 þ radiotherapy under low oxygen concen-
trations versus 1.49 for TH-302 þ radiotherapy under 21% O2
concentrations (Supplementary Fig. S3D and Supplementary
Table S2).
No toxic effects were observed for the different treatments in
any of the groups as monitored by following changes in body
weight (Supplementary Fig. S4A and S4B).
Oxygen modification and hypoxic fraction
To assess the effect of TH-302 treatment in combination with
oxygen modification on the HF, a [18F]HX4 scan was acquired
before and after treatment on the rhabdomyosarcoma histologic
controlanimals.TheHFofambient airbreathinganimalsdecreased
from 23%  6.7% at baseline to 2.5%  4.2% after TH-302
treatment. For 95% oxygen breathing animals, the HF was low
before the start of the treatment, and this remainedunchanged after
Figure 2.
The effect of oxygen modification on
the combination treatment of TH-302
and radiotherapy. A, exposing
animals to 95% oxygen (nicotinamide
500 mg/kg i.p./carbogen breathing
95% oxygen, 5% CO2), or 7% oxygen
(residual N2) decreases or increases
the HF, respectively, before the start
of treatment compared with 21%
oxygen breathing (ambient air).
Representative [18F]HX4 PET images
with the delineation of the tumor in
black and the HF in red.  , P < 0.05;
 , P < 0.0001. Exposing the (B)
rhabdomyosarcoma (n  7) or (C)
H460 (n  8) model to modifying
oxygen concentrations for the
duration of the treatment for 4 and
2.5 hours per day, respectively. Data,
mean  SEM.
Peeters et al.
Clin Cancer Res; 21(13) July 1, 2015 Clinical Cancer Research2988
on July 22, 2021. © 2015 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst March 24, 2015; DOI: 10.1158/1078-0432.CCR-15-0018 
eitherNaClorTH-302administration(Fig. 3A).The spread inHFof
7% oxygen breathing animals was very large. On average, the HF
after treatment was lower than before treatment independent of
NaCl or TH-302 treatment although this was not significant.
The HF in the H460 model was determined after the last TH-
302 injection using pimonidazole staining. TH-302 treatment
significantly reduced the HF compared with the control animals
(Figs. 1D and 3B). The different oxygen breathing conditions
revealed a similar pattern; in combination with 95% oxygen
breathing control, animals had a HF of 10.0%  5.9%, whereas
animals treated with TH-302 had a HF of 2.1%  1.0%. Animals
exposed to low oxygen concentrations in combination with NaCl
Figure 3.
The effect of TH-302 treatment and
oxygen modification on the HF.
A, HF was measured in the
rhabdomyosarcoma model (n ¼ 6)
using [18F]HX4 hypoxia PET imaging
the day before treatment and the last
day of treatment with either control
(NaCl) or TH-302 in combination with
95% oxygen (nicotinamide and 95%
O2 breathing), ambient air, or 7%
oxygen. B, pimonidazole staining was
used to determine the HF after
treatment in the H460 model. Top, a
representative image is depicted per
group. Bottom, quantification per
group (n¼6).  ,P<0.05;  ,P<0.005.
TH-302 and Radiotherapy Monitored by [18F]HX4 Imaging
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had aHF of 8.4% 4.5%, which was lower in the animals treated
with TH-302 (1.1%  1.0%). Furthermore, TH-302–treated
tumors had a decreased necrotic fraction, although this was only
significant when animals were exposed to 21% oxygen. No
differences were observed in the relative vessel area or perfusion
(Supplementary Fig. S5).
Furthermore, we investigated whether the HF at the start of the
therapy was associated with the treatment outcome expressed as
T4SV. The T4SV for TH-302–treated tumors increased with
increasing HF at onset meaning that 95% oxygen breathing
animals reached their endpoint first, followed by ambient air
and then 7% oxygen breathing animals (Fig. 4). The control
animals, with or without radiotherapy, did not show this
association.
Discussion
This study demonstrates the combination efficacy of the HAP
TH-302 with radiotherapy in two preclinical tumor models,
whichwas causally related to the tumoroxygen status. In addition,
the [18F]HX4 determined HF was associated with the treatment
outcome.
Pharmacokinetic studies in nontumor-bearing rats showed no
adverse effects when the animals were treated with TH-302 (17).
Although rhabdomyosarcoma-bearing rats showed no adverse
effect after a 25 mg/kg TH-302 dose, dose-dependent adverse
effects, such as a significant drop in body weight, diarrhea, and
general malaise, were observed after higher dosing. Initial clinical
studies also reported some adverse effects with skin and mucosal
toxicities being dose limiting, while common adverse events were
nausea, skin rash, fatigue, and vomiting (5, 6).
In this study, two different methods were used to assess the HF:
noninvasive, clinically used [18F]HX4 PET imaging (11, 13), and
IHC of pimonidazole adducts (9). Although [18F]HX4 hypoxia
PET imaging represents the whole tumor in a noninvasive, repro-
ducible, three-dimensional manner, IHC stainings can, in addi-
tion to hypoxia, extract more tumor microenvironmental infor-
mation from the same tumor section. In both techniques,
[18F]HX4 and pimonidazole are reduced under low oxygen con-
centrations (18) and a significant colocalization relationship was
demonstrated at the tumor subregional level (9). Although mon-
itored by different techniques, these data indicate that TH-302 has
the same reducing effect on the HF in both tumor models.
Furthermore, based on these data, [18F]HX4 imaging could be
used as biomarker of response in a window-of-opportunity clin-
ical trial. By performing a pretreatment scan, the initial tumor HF
can be determined, followed by a single injection of TH-302. A
posttreatment [18F]HX4hypoxia scan can assess whether there is a
response in HF to this HAP, without interference of other anti-
cancer therapies. This new approach is designed to test new
molecular entities in a clinical trial while being cost and patient
efficient (19, 20).
A correlation has previously been reported between theHF and
the tumor growth inhibition in xenograft models (3). This
endorses our findings of a pronounced effect of TH-302 because
the preclinical tumor models in this study were observed to have
respectively somewhat higher and lower HF than the reported HF
of 18.6% for rhabdomyosarcoma (15) and 16.3% for H460 (3).
Although the HF in tumors was significantly decreased after TH-
302 treatment, not all hypoxic cells were eliminated, as observed
in both tumor models. The remaining hypoxic cells might be
resistant, unreachable by TH-302, or caused by cycling hypoxia. In
addition to the decrease in the HF, this study shows a decrease in
the necrotic fraction of the TH-302–treated tumors. This indicates
that the dead cells are resorbed, which is supported by the
stagnation in tumor growth after 3 days of TH-302 treatment.
Other microenvironmental characteristics like relative vessel area
and perfusion were not affected by TH-302 treatment, suggesting
that the tumormaintains its vasculature. This is in agreement with
previously published results on solid tumors (3).
Although TH-302 exhibits antitumor effects as amonotherapy,
it has been shown that its therapeutic efficacy increases
when combined with conventional anticancer therapies mainly
targeting the nonhypoxic cells. On the basis of favorable out-
comes of two clinical phase II trials (7, 8), phase III trials in
metastatic or locally advanced unresectable pancreatic adenocar-
cinoma (NCT01746979) and advanced soft-tissue sarcoma
(NCT01440088) are currently ongoing. However, to our knowl-
edge, no study has investigated the combination treatment of
TH-302 with radiotherapy and [18F]HX4 hypoxia imaging. This
combination is thought to be effective especially because radio-
therapy can be locally applied, specifically targeting the tumor
while preserving normal tissue. In this study, we show that this
combination is effective and causes a delayed tumor growth and
increased T4SV for both investigated tumormodels, confirming
the hypothesis that the combination therapy of TH-302 and
radiotherapy will lead to an enhanced therapeutic effect. In the
Figure 4.
The association between the pretreatment [18F]HX4-based HF and the
treatment outcome in rhabdomyosarcoma tumors. HF (%) as measured
before the start of the treatment plotted to the time to reach four times the
start volume (T4SV) for the control group (NaCl) and animals treated with
TH-302 either with or without radiotherapy. HF is determined using [18F]HX4
hypoxia PET imaging after 95% oxygen breathing (n ¼ 32), ambient air
breathing (n ¼ 43) and 7% oxygen breathing (n ¼ 33). The T4SV is
calculated forNaCl for all oxygen concentrations using 8 animals, TH-302 95%
oxygen (n ¼ 7), ambient air and 7% oxygen (n ¼ 8). Data, mean  SEM.
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rhabdomyosarcoma tumor model, TH-302 treatment was com-
bined with a single dose of 4, 8, and 12 Gy of radiotherapy
resulting in a dose-dependent effect. In subsequent studies, the
single radiotherapy dose of 8 Gy was used, reasoning that the
regrowth of the tumor solely depends on hypoxic cells (21),
providing a basis for TH-302 efficacy. This approach is different
from clinical practice where fractionated radiotherapy schedules
are used. By applying 2 Gy fractions to the tumor, reoxygenation
occurs and the HF gradually decreases (22, 23). We speculate that
the combination of TH-302with fractionated radiotherapywould
also increase the therapeutic effect of the radiotherapy because the
HF is reduced by the pretreatment of TH-302, increasing the
potential of radiotherapy.
In this study, we further wanted to elucidate whether TH-302
efficacy is dependent on the tumor oxygen status. Exposing
animals to either nicotinamide and carbogen or 7% oxygen
breathing has been demonstrated to be effective in modulating
theHF in tumors (9, 24, 25). Altering oxygen breathing before the
TH-302 treatment did modify the tumor HF in rhabdomyosar-
coma animals as measured by [18F]HX4. However, in the H460
model, theHFwas determined only after TH-302 treatment and at
this point no differences were observed in control animals of the
various oxygen modifications. A possible explanation would be
that the mice adapted to the oxygen breathing schedule, prevent-
ing the tumor HF from changing, which has been observed for
mice exposed to long-term carbogen breathing (26, 27). In the
rhabdomyosarcomamodel, the tumor growth of control animals
was significantly reduced upon oxygen modification as well as in
the mice exposed to 7% oxygen breathing mice. No effect on
tumor growth was observed after oxygenmodification in another
study using H460 tumors exposed to 95% or 10% oxygen breath-
ing (3). This unexpected finding could possibly be explained by
the stress induced by the exposure to the oxygen modifications,
although TH-302 or radiotherapy treatment groups did not seem
to be influenced by this. However, by calculating the enhance-
ment ratio, these oxygen modification effects are taken into
account. Despite these effects on growth delay, a positive effect
of the therapy is observed. Radiotherapy was applied 1 hour after
carbogen breathing without any beneficial effect. This can be
explained by the fact that tumor oxygen concentrations return
to pre-carbogen levels within 1 minute after stopping carbogen
treatment as detected by Eppendorf electrodemeasurements (28).
Furthermore, clinical studies have shown that the presence of
hypoxia and the pretreatment selection of patients with hypoxic
tumors is essential for the combination of nicotinamide admin-
istration and carbogen breathing to be effective (29, 30). Breath-
ing low oxygen concentrations reduced the effect of radiotherapy
in the H460 model, indicating that, although not detected on
pimonidazole IHC staining, low oxygen concentrations counter-
acted the irradiation. The effect of TH-302 is abolished by carbo-
gen breathing in the rhabdomyosarcoma model independent of
radiotherapy. This can be explained by the reduced HF leaving
almost no cells present to convert TH-302 into its cytotoxic
metabolite. For the H460 model the HF did not decrease upon
carbogen breathing what reflects in the unchanged tumor growth
compared with control tumors. Upon radiotherapy, however,
there is a trend toward a faster tumor growth that also indicates
abolishment of the TH-302 efficacy. In tumors with an enlarged
HF, TH-302 caused a slight, nonsignificant, delay in tumor growth
compared to TH-302 under normal air conditions.Moreover, TH-
302 decreased the HF to almost zero under ambient air condi-
tions, while with 7% oxygen breathing the HF is still 28%.
Although this result could be caused by the counteracting effects
of TH-302 reducing the HF and the 7% oxygen breathing increas-
ing theHF,we speculate that it is caused by a limited availability of
TH-302 to target all hypoxic cells. In H460 tumors, 7% oxygen
breathing resulted in an increased therapeutic effect with an
enhancement ratio of 2.2 for TH-302 alone and 2.5 for the
combination therapy of TH-302 and radiotherapy. This result
demonstrates that when sufficient TH-302 is present, more TH-
302 is reduced upon low oxygen concentrations, causing an
increased cytotoxicity.
A causal relation between the pretreatment HF measured by
[18F]HX4and the TH-302 treatment outcomewasobserved. These
results indicate that pretreatment evaluationof hypoxia couldbe a
useful tool in selecting tumors that benefit from the additional
hypoxia targeting treatment. This hypoxia-based patient selection
could also be used in other therapy strategies for instance to target
hypoxic subvolumes by escalate radiation dose (31). Further-
more, this information could be implemented in decision–sup-
port systems to predict tumor response and optimize patient
therapy (32). These applications demonstrate the importance of
gaining pretreatment information by hypoxia imaging.
Conclusion
This study demonstrates that TH-302 treatment together with
conventional radiotherapy is a promising combination with an
increased therapeutic potential, and warrants further testing.
Furthermore, detecting the tumor HF by [18F]HX4 PET imaging
may allow the ability to predict which patients will benefit most
from the hypoxia targeted TH-302 treatment and gives the pos-
sibility to noninvasivelymonitor TH-302 efficacy in the context of
window-of-opportunity trials. On the basis of this preclinical
study, we suggest a clinical trial for treating patients with the
combination of TH-302 and radiotherapy while monitoring the
HF before and during the treatment.
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